share_log

金斯瑞生物科技(01548.HK):传奇生物宣布美国FDA批准CARVYKTI用于复发或难治性多发性骨髓瘤患者二线治疗

Kingsley Biotechnology (01548.HK): Legendary Biotech announced that the US FDA approved CARVYKTI for second-line treatment of patients with recurrent or refractory multiple myeloma

Gelonghui Finance ·  Apr 8 07:45

Glonghui, April 8 | Kingsley Biotechnology (01548.HK) announced that Legend Biotechnology Co., Ltd. (“Legend Biotech”, a non-wholly-owned subsidiary of the company and its shares are listed on the US NASDAQ Global Select Market in the form of American Depositary Shares) has submitted Form 6-K to the US Securities Regulatory Commission on April 5, 2024, and announced that the US Food and Drug Administration (“US FDA”) has approved CARVYKTI(Sidakiolenthel, cilta-cel) is used to treat adult patients with recurrent or refractory multiple myeloma who have received at least previous first-line treatment (including proteasome inhibitors and immunomodulators) and are resistant to lenalidomide.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment